{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:20:55Z","timestamp":1772166055140,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-025-12816-4","type":"journal-article","created":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T23:39:51Z","timestamp":1746401991000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of generic antiretroviral drugs introduction on pharmaceutical expenditure patterns in the Netherlands: a six-year retrospective database analysis from 2016 to 2022"],"prefix":"10.1186","volume":"25","author":[{"given":"P.","family":"Oosterhof","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Van Luin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. W.","family":"Vanhommerig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Brinkman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. M.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"12816_CR1","unstructured":"van Sighem AI, Wit FWNM, Boyd A, Smit C, Matser A, van der Valk M. Monitoring Report 2022. Human Immunodeficiency Virus (HIV) Infection in the Netherlands. Amsterdam: Stichting HIV Monitoring, 2022; 2022. Available online at: www.hiv-monitoring.nl."},{"key":"12816_CR2","unstructured":"Rijksinstituut voor Volksgezondheid en Milieu(RIVM). Kosten van ziekten; hiv en aids. the Netherland. Available from: https:\/\/www.vzinfo.nl\/soa\/zorguitgaven. Accessed 31 Oct 2023."},{"issue":"8","key":"12816_CR3","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1586\/14787210.2014.928589","volume":"12","author":"GP Wormser","year":"2014","unstructured":"Wormser GP, Lappas T. Is there a role for generic antiretroviral drugs in the united States? Expert Rev Anti Infect Ther. 2014;12(8):897\u20139.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"12816_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/s12879-015-1077-7","volume":"15","author":"U Restelli","year":"2015","unstructured":"Restelli U, Scolari F, Bonfanti P, Croce D, Rizzardini G. New highly active antiretroviral drugs and generic drugs for the treatment of HIV infection: a budget impact analysis on the Italian National health service (Lombardy region, Northern Italy). BMC Infect Dis. 2015;15:323.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"12816_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.medmal.2016.01.003","volume":"46","author":"Y Yazdanpanah","year":"2016","unstructured":"Yazdanpanah Y, Schwarzinger M. Generic antiretroviral drugs and HIV care: an economic review. Med Mal Infect. 2016;46(2):67\u201371.","journal-title":"Med Mal Infect"},{"key":"12816_CR6","unstructured":"van Lessen Kloeke KLA. Pricing & reimbursement laws and regulations 2023. Netherlands: Insights GL; 2023."},{"key":"12816_CR7","unstructured":"Government of the Netherlands. Keeping medicines affordable. 2023. https:\/\/www.government.nl\/topics\/medicines\/keeping-medicines-affordable. Accessed 13 Nov 2023."},{"key":"12816_CR8","unstructured":"Foundation for Pharmaceutical Statistics(SFK). Facts and Figures\u2013\u20092022 the Netherlands. Available from: https:\/\/www.sfk.nl\/english. Accessed Nov 2023."},{"key":"12816_CR9","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. ATC classification system. Available from: https:\/\/www.whocc.no\/atc\/structure_and_principles\/. Accessed 31 Oct 2023."},{"key":"12816_CR10","unstructured":"World Health Organization(WHO). Defined Daily Dose (DDD). Available from: https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/about-ddd. Accessed 31 Oct 2023."},{"key":"12816_CR11","unstructured":"Geneesmiddel Informatie Centrum (GIC) I. G-standaard. Available from: https:\/\/www.z-index.nl\/g-standaard. Accessed 31 Oct 2023."},{"key":"12816_CR12","unstructured":"Kosten van medicijnen. the Netherlands; 2023. Available from: https:\/\/www.medicijnkosten.nl. Accessed 31 Oct 2023."},{"key":"12816_CR13","unstructured":"Oosterhof PvLM, Brinkman B, Burger DB. Large cost-savings of splitting a single-tablet regimen (STR) to a two-tablet regimen (TTR), containing the same antiretrovirals (the SPLIT study). 12th Netherlands Conference on HIV Pathogenesis, Epidemiology, Prevention & Treatment. Amsterdam: NCHIV \u201819; 2019."},{"key":"12816_CR14","unstructured":"Nederlandse Vereniging voor Hiv Behandelaren (NVHB). Informatie Hiv Vereniging betreffende hiv- zorg voor mensen uit Oekra\u00efne [press release]. Available from: https:\/\/nvhb.nl\/2022\/05\/17\/informatie-hiv-vereniging-betreffende-hiv-zorg-voor-mensen-uit-oekraine\/. Accessed 31 Oct 2023."},{"issue":"1","key":"12816_CR15","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1186\/s12913-022-07859-w","volume":"22","author":"R Demeulemeester","year":"2022","unstructured":"Demeulemeester R, Savy N, Mouni\u00e9 M, Molinier L, Delpierre C, Dellamonica P, et al. Economic impact of generic antiretrovirals in France for HIV patients\u2019 care: a simulation between 2019 and 2023. BMC Health Serv Res. 2022;22(1):567.","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"12816_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.healthpol.2018.01.002","volume":"122","author":"J Rwagitinywa","year":"2018","unstructured":"Rwagitinywa J, Sommet A, Palmaro A, Montastruc JL, Lapeyre-Mestre M. Utilization and costs of HIV antiretroviral drugs in Europe during the last ten years: impact of generic antiretroviral drugs on cost reduction. Health Policy. 2018;122(3):237\u201342.","journal-title":"Health Policy"},{"issue":"1","key":"12816_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12913-021-07390-4","volume":"22","author":"M Lottes","year":"2022","unstructured":"Lottes M, Bremer V, Prugger C, Kollan C, Schmidt D. Cost-savings and potential cost-savings through the distribution of generic antiretroviral drugs within the statutory health insurance market of Germany between January 2017 and June 2019. BMC Health Serv Res. 2022;22(1):63.","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"12816_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S2055-6640(20)30871-2","volume":"2","author":"AM Hill","year":"2016","unstructured":"Hill AM, Pozniak AL. How can we achieve universal access to low-cost treatment for HIV? J Virus Erad. 2016;2(4):193\u20137.","journal-title":"J Virus Erad"},{"issue":"7","key":"12816_CR19","doi-asserted-by":"publisher","first-page":"520","DOI":"10.2471\/BLT.08.058925","volume":"87","author":"B Waning","year":"2009","unstructured":"Waning B, Kaplan W, King AC, Lawrence DA, Leufkens HG, Fox MP. Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases. Bull World Health Organ. 2009;87(7):520\u20138.","journal-title":"Bull World Health Organ"},{"issue":"1","key":"12816_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1185\/03007995.2013.844685","volume":"30","author":"I Aldir","year":"2014","unstructured":"Aldir I, Horta A, Serrado M. Single-tablet regimens in HIV: does it really make a difference? Curr Med Res Opin. 2014;30(1):89\u201397.","journal-title":"Curr Med Res Opin"},{"key":"12816_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.11606\/S1518-8787.2018052000399","volume":"52","author":"JO Costa","year":"2018","unstructured":"Costa JO, Ceccato M, Silveira MR, Bonolo PF, Reis EA, Acurcio FA. Effectiveness of antiretroviral therapy in the single-tablet regimen era. Rev Saude Publica. 2018;52:87.","journal-title":"Rev Saude Publica"},{"key":"12816_CR22","unstructured":"Nederlandse Vereniging voor Hiv behandelaren(NVHB). Kostenoverzicht anti-retrovirale middelen. Available from: https:\/\/richtlijnhiv.nvhb.nl\/index.php\/Inhoud. Accessed 31 Oct 2023."},{"key":"12816_CR23","unstructured":"Stichting Farmaceutische Kengetallen(SFK)SFK. E\u00e9n-pil-per-dag bij 37% van hiv-verstrekkingen. Available from: https:\/\/www.sfk.nl\/publicaties\/PW\/2021\/een-pil-per-dag-bij-37-van-hiv-verstrekkingen. Accessed 31 Oct 2023."},{"key":"12816_CR24","unstructured":"Ministerie van Binnenlandse Zaken en Koninkrijksrelaties. Wet geneesmiddelenprijzen. https:\/\/wetten.overheid.nl\/. Accessed 31 Oct 2023."},{"key":"12816_CR25","unstructured":"Stichting Farmaceutische Kengetallen (SFK). Gemiddelde prijsdaling oktober bedraagt 0,5%. Available from: https:\/\/www.sfk.nl\/publicaties\/PW\/2023\/gemiddelde-prijsdaling-oktober-bedraagt-0-5. Accessed 31 Oct 2023."}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12816-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-025-12816-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12816-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T23:39:57Z","timestamp":1746401997000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-025-12816-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12816"],"URL":"https:\/\/doi.org\/10.1186\/s12913-025-12816-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3923450\/v1","asserted-by":"object"}]},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]},"assertion":[{"value":"3 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study utilized an existing database (Foundation for Pharmaceutical Statistics - SFK) in the Netherlands which aggregates anonymized pharmacy data for research purposes. As such, individual patient consent was not required and the study did not involve direct participation. The use of this database for research has been approved by the SFK committee, ensuring compliance with national guidelines for data privacy and ethical research conduct (Foundation for Pharmaceutical Statistics \u2014 SFK Website).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PO received personal consulting fees from ViiV healthcare, Gilead, and Merck Sharp & Dohme. KB received personal consultation fees from Merck, Gilead, and ViiV. KB has received a writing honorarium from UpToDate. The remaining authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"643"}}